Asploro Cardiovascular Case Reports and Research

Asploro Cardiovascular Case Reports and Research

Hiroshi Bando^1,2iD*
1Medical Research/Tokushima University, Tokushima, Japan
²Japan Low Carbohydrate Diet Promotion Association, Kyoto, Japan

Corresponding Author: Hiroshi Bando ^{ORCID iD}
Address: Tokushima University /Medical Research, Nakashowa 1-61, Tokushima 770-0943, Japan.
Received date: 20 May 2024; Accepted date: 20 June 2024; Published date: 26 June 2024

Citation: Bando H. Latest Trends of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2-I) for Heart Failure (HF) and Chronic Kidney Disease (CKD). Asp Cardio Case Rep and Res. 2024 Jun 26;1(1):5-8.

Copyright © 2024 Bando H. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.

Keywords: Empagliflozin, DAPA-HF, EMPA-ELDERLY, American College of Physicians (ACP), Grading of Recommendations Assessment, Development and Evaluation (GRADE)

Abbreviations: ACP: American College of Physicians; GRADE: Grading of Recommendations Assessment, Development and Evaluation

Abstract

Sodium-glucose cotransporter-2 inhibitors (SGLT2-i) have been effective for heart failure (HF), chronic kidney disease (CKD), and type 2 diabetes (T2D). Among SGLT2-i, empagliflozin and dapagliflozin were compared for clinical effect, with empagliflozin showing a lower composite of all-cause mortality or hospitalization with a hazard ratio (HR) of 0.90. In the EMPA-ELDERLY clinical trial, empagliflozin demonstrated better HbA1c reduction and weight reduction without affecting muscle strength or mass in elderly patients with T2D. The American College of Physicians (ACP) published “Newer Pharmacologic Treatments in Adults with Type 2 Diabetes” in April 2024. The potential mechanisms for the anti-inflammatory effects of SGLT2-i will be clarified in the future.